Login

Incentives For Generating More IP Commercialization Opportunities

Henry FradkinValue Extraction, LLC, Principal, Dearborn, MI, USA I don’t think I have to belabor the point… this is really a tough economy. Based on at least what I am seeing and echoed by others in the IP and technology commercialization business, it appears that most “licensing” deals are the result of successful patent assertions […]

The Project For A Uniform European Union (EU) Patent And A Unified Patent Litigation System Within The EU: Closer Than Ever, But With Some Detractors

José Miguel LissénIP Litigator, Senior Associate, Gómez-Acebo & Pombo, Abogados, S.L.P., Madrid, Spain Sergio PozaIP Litigator, Associate, Gómez-Acebo & Pombo Abogados, S.L.P. , Abogado, Madrid, Spain In Europe, patent protection granted by the national patent systems through an application filed with the national patent office coexists with the protection granted by the so-called European Patent […]

IPR-Codes And Guidelines In Europe Facilitating Collaboration Of Publicly Funded Research Organizations (PROs) With Businesses Part 1

Thomas L. BereuterGraz University of Technology, Vienna, Austria David JerolitschCEST, Wiener Neustadt, Austria Peter G. HeimerlVienna University of Technology, Vienna, Austria Effective and efficient technology transfer by collaborative R&D between universities or other publicly-funded organizations and businesses is rewarding and necessary, but a challenge. Negotiation of the terms for the collaboration often proves to be […]

License Compliance Issues For Biopharmaceuticals: Special Challenges For Negotiations Between Companies And Non-Profit Research Institutions

Todd A. PonzioPhD, National Cancer Institute Technology Transfer, Fellow, Rockville, MD, USA Hans FeindtPhD, NIH Office of Technology Center, Chief, Monitoring and Enforcement Branch, Rockville, MD, USA Steven FergusonCLP, NIH Office of Technology Transfer, Deputy Director, Licensing & Technology Transfer, Rockville, MD, USA Biopharmaceuticals are therapeutic products based on biotechnology. They are manufactured by or […]

A Simple Method For Calculating A “Fair” Royalty Rate

Damien SalauzeInstitut Curie VP, Business Development & Licensing, Paris, France During a licensing deal (i.e. license of a patent protecting a product), several methods are commonly used to determine what is intended to be a “fair” royalty rate. It is even recommended to combine several methods in order to cross-check that there is no discrepancy […]

Backing Up The Claim: Reverse Engineering Enables Successful Patent Licensing

Terry LudlowChipworks Founder, Chairman and CEO, Ottawa, Canada Mike ThummChipworks, VP Patent Intelligence, Ottawa, Canada Andrea GironesPatent Advisor to Chipworks, Ottawa, Canada Intellectual Property licensing is becoming a key aspect of leading corporations’ strategic business plans. And, finding and proving infringement of your patents is the essential foundation of any successful licensing campaign. More and […]

Intellectual Property Valuation Approaches And Methods

Robert F. ReillyCPA Managing Director, Willamette Management Associates, Chicago, IL, USA There are numerous reasons to value an owner/operator’s intellectual property. All of these reasons may be generally grouped into the following categories: transactions, financings, taxation, regulatory, bankruptcy, accounting, litigation, and strategic planning. Valuation analysts are often asked to value intellectual property for these various […]

Recent Entire Market Value Rule Opinions Impact Patent Valuation

Drew VothGrant Thornton, LLP, Director, Seattle, WA, USA David H. BinneyK & L Gates, LLP, Partner, Seattle, WA, USA Mega-damages jury awards in patent infringement cases are piling up: Lucent is awarded $358 million in a matter against Microsoft and others; Uniloc is awarded $388 million in a matter against Microsoft; Cornell University is awarded […]

Search LESI

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors